Kai Chieko

last updated 2021-12-13

EVENTS

2020.10.9
The co-authored paper with Dr Nikaido was published in DNA Research
2020.8.31
The project proposal for the development of a measles vector based COVID-19 vaccine was accepted by the Japan Agency for Medical Research and Development (AMED)
2020.6.1
Akihiro Sugai's paper was published in BBRC
2020.5.18
The co-authored paper with Dr Hai-Ying was published in Plos One
2020.3.13
The project proposal for clinical research to develop oncolytic therapy using recombinant measles rMV SLAM blind was accepted by the Japan Agency for Medical Research and Development (AMED)
2019.12.17
We had a Kai Lab Opening Party at IIS.See details.here
2019.12.9-10
Dr.Kai has given an invited lecture at the Nipah Virus International Conference. "Developmant of measles virus vectoe vaccine for Nipah virus infection
2019.10.29
Dr. Moritoh has given oral presentation at the 67th Annuam Meeting of the Japanese Society for Virology.
2019.9.30
Institute of Industrial Science Open Symposium, co-sponsored by Coalition for Epidemic Preparedness Innovations (CEPI), was held at the Tokyo University.
New Vaccine for Saving Lives ~Focusing on Nipah Virus Infection~
2019.9.26-28
Dr.Fujiyuki, Dr.Moritoh, and Mr.Tamura have given oral presentation at The 78th Annual Meeting of the Japanese Cancer Association (Kyoto).
2019.9.3
Kai laboratory has moved from the Institute of Medical Science to the Institute of Industrial Science.
2019.3.12
Memorial Lecture was held to celebrate the retirement of Dr. Kai. See the detail here.
2018.10.28-30
Dr.Uchida and Dr.Morito have given oral presentations, and Dr. Sugai has given a poster presentation at The 66th Annual Meeting of the Japanese Society for Virology (Kyoto).

CEPI awarded contract worth up to US$31 million to the University of Tokyo to develop vaccine against Nipah virus

The Coalition for Epidemic Preparedness Innovations (CEPI) is funded by the Wellcome Trust, the Bill and Melinda Gates Foundation, the World Economic Forum, the governments of Norway, Germany, Japan, and India. Its aim is to accelerate the development of early phase of vaccines against emerging diseases to prepare for the future epidemics. For the detail of CEPI, please see here.


To see the press release from the University of Tokyo and CEPI,
please click the following LOGOs.



Research done by Dr. Chieko Kai and Misako Yoneda was highly evaluated by CEPI. Kai Laboratory will further focus on Nipah vaccine development to succeed in the project. For the detail of the project, please see here.

RESEARCH